No black box warning on record for Divalproex Sodium Er

As of the latest FDA labeling reviewed, Divalproex Sodium Er (DIVALPROEX SODIUM ER) does not carry a black box warning. Standard warnings and precautions still apply — see the full Divalproex Sodium Er medicine page for the complete safety profile.

Other warnings & precautions

5.1 Hepatotoxicity General Information on Hepatotoxicity Hepatic failure resulting in fatalities has occurred in patients receiving valproate. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a

No black box warning on record for Divalproex Sodium Er

Other warnings & precautions

5.1 Hepatotoxicity General Information on Hepatotoxicity Hepatic failure resulting in fatalities has occurred in patients receiving valproate. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a

Divalproex Sodium Er Black Box Warning

No black box warning on record for Divalproex Sodium Er

Other warnings & precautions

Divalproex Sodium Er Black Box Warning

No black box warning on record for Divalproex Sodium Er

Other warnings & precautions